Pressure BioSciences, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Provides Business Update

SOUTH EASTON, MA--(Marketwired - March 22, 2017) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2016, provided a business update, and offered limited guidance for FY2017.

Financial Results: Q4 2016 vs. Q4 2015
Products and services revenue was $365,262 in the fourth quarter of 2016 compared to $235,600 in the same quarter of 2015, a 55% increase. Sales of consumables were $50,054 for the fourth quarter ended December 31, 2016 compared to $29,521 for the same period in 2015, an increase of 70%. Grant revenue for Q4 2016 was $54,449 compared to $128,519 for the same period in 2015.

Total revenue for the fourth quarter ended December 31, 2016 was $419,711 compared to $364,119 for the same period in 2015, a 15% increase. This increase was due to products and services sales growth.

Operating loss for Q4 2016 was $1,177,205 compared to a loss of $935,746 for the same period in 2015. This increase was due primarily to inventory valuations and increases in marketing/IR activities, off-set by an increase in total revenue.

Income per common share -- basic -- was $0.10 for Q4 2016 compared to a loss per common share of $0.19 for the same period in 2015. Income per common share -- diluted -- was $0.03 for Q4 2016 compared to a loss per common share of $0.19 for the same period in 2015.

Financial Results: FY2016 vs. FY2015
Products and services revenue was $1,794,749 in the year ended December 31, 2016 compared with $1,409,991 in the year ended December 31, 2015, a 27% increase. Sales of consumables were $199,873 for the year ended December 31, 2016 compared to $146,408 for the same period in 2015, an increase of $53,465 or 37%. Grant revenue for fiscal year 2016 was $181,738 compared to $387,700 for the 2015 fiscal year.

Total revenue for the fiscal year ended December 31, 2016 was $1,976,487 compared to $1,797,691 for the same period in 2015, a 10% increase. This increase was due to products and services sales growth.

Operating loss for the year ended December 31, 2016 was $3,735,653 compared to a loss of $3,565,182 for the same period in 2015. This increase in operating loss was due primarily to increases in R&D, Sales and Marketing, and IR expenses, off-set to a certain extent by an increase in total revenue.

Loss per common share -- basic and diluted -- was $0.10 for the year ended December 31, 2016 and $0.36 for the same period in 2015.

Financial and Operational Highlights: FY2016 & Q1 2017

  • January 2016: SCIEX, a global life sciences leader and subsidiary of Danaher Corp, announced a co-marketing agreement with PBI to improve protein quantification in complex samples.
  • February: SCIEX and Children's Medical Research Institute (Sydney, Australia) announced a partnership to advance the promise of precision medicine and stated they would benefit from SCIEX's collaboration with PBI and our PCT platform for increased protein quantitation and reproducibility.
  • March: PBI participated in a SCIEX workshop on new innovations in industrialized proteomics, marking the first time the two companies had presented together under their co-marketing agreement.
  • Q1 2016: $1.4M was received in a private placement of fixed-rate convertible debentures, bringing the total raised in our $5M PIPE to an over-subscribed $6.3M. All five PBI Board members participated.
  • April: PBI was added to the high-performing Richmond Club Index.
  • June: Scientists from six separate research groups made presentations at the American Association for Mass Spectrometry Annual Meeting on the compelling advantages of the PCT Platform.
  • July: We announced the initial shipment of the next-generation Barocycler 2320EXTREME to the Australian cancer research group ProCan, a collaborator in the U.S.'s Cancer Moonshot initiative.
  • September: PBI was invited, along with SCIEX, CMRI, Institute of Molecular Systems Biology (Zurich, CH), Beckman-Coulter, Ilumina, and Next-Bio to present at the Gala Opening of the ProCan cancer research center.
  • October: We announced the close of a $2M line-of-credit under favorable terms to PBI shareholders.

  • February 2017: We announced CE Marking for our new, next-generation Barocycler 2320EXTREME, giving us access to 31 countries in Europe that require the CE Mark prior to product commercialization in Europe.
  • March: The Barocycler 2320EXTREME received the 2017 North American Excellence Award for "Best New Instrument for Sample Preparation" from Corporate America News, with a subscription list of over 135,000.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017. These accomplishments have let us enter the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; important additions to our hard-working and talented staff; a larger customer base; and an expanded and enhanced sales and marketing capability."

Mr. Schumacher continued: "Our near-term goals are clear, focused, and attainable in 2017. We believe their achievement will subsequently position PBI to be a stronger, more valuable company. These goals include: (i) an up-list to the NASDAQ stock market in Q2 2017, (ii) measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity, (iii) continuation of the current expansion of our sales and marketing capabilities, and our reach into new countries, investigators, and fields-of-use; and (iv) a focus on sales, sales, and sales."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Wednesday, March 22, 2017. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBIO Fourth Quarter and Fiscal Year 2016 Financial Call, ID 10291.
Replay Number (877) 481-4010; (919) 882-2331 (International). Teleconference Replay Available for 30 days.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the year ended December 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

                                                                            
                  PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY                 
                    CONSOLIDATED STATEMENTS OF OPERATIONS                   
                                                                            
                       For the Three Months Ended     For the Year Ended    
                              December 31,               December 31,       
                       --------------------------  ------------------------ 
                           2016          2015          2016         2015    
                       ------------  ------------  -----------  ----------- 
Revenue:                                                                    
Products, services,                                                         
 other                 $    365,262  $    235,600  $ 1,794,749  $ 1,409,991 
Grant revenue                54,449       128,519      181,738      387,700 
                       ------------  ------------  -----------  ----------- 
  Total revenue             419,711       364,119    1,976,487    1,797,691 
                       ------------  ------------  -----------  ----------- 
                                                                            
Costs and expenses:                                                         
Cost of products and                                                        
 services                   106,314        33,274      834,012      609,054 
Research and                                                                
 development                257,996       226,396    1,183,011    1,105,295 
Selling and marketing       262,864       171,285      872,365      745,574 
General and                                                                 
 administrative             969,742       868,910    2,822,752    2,902,950 
                       ------------  ------------  -----------  ----------- 
  Total operating                                                           
   costs and expenses     1,596,916     1,299,865    5,712,140    5,362,873 
                       ------------  ------------  -----------  ----------- 
                                                                            
  Operating loss         (1,177,205)     (935,746)  (3,735,653)  (3,565,182)
                                                                            
Other (expense)                                                             
 income:                                                                    
Interest expense, net    (1,539,478)   (1,315,310)  (4,501,186)  (4,146,416)
Other expense                     -            31       (1,112)     (36,879)
Impairment loss on                                                          
 investment                (373,682)            -     (373,682)           - 
Gain on extinguishment                                                      
 of embedded                                                                
 derivative                                                                 
 liabilities                      -       526,856            -    2,555,180 
Change in fair value                                                        
 of derivative                                                              
 liabilities              6,317,149    (2,260,969)   5,904,649   (2,222,001)
                       ------------  ------------  -----------  ----------- 
  Total other                                                               
   (expense) income       4,403,989    (3,049,392)   1,028,669   (3,850,116)
                       ------------  ------------  -----------  ----------- 
                                                                            
Net income (loss)         3,226,784    (3,985,138)  (2,706,984)  (7,415,298)
                       ------------  ------------  -----------  ----------- 
Accrued dividends on                                                        
 convertible preferred                                                      
 stock                            -        (1,426)           -      (23,194)
                       ------------  ------------  -----------  ----------- 
Net income (loss)                                                           
 applicable to common                                                       
 shareholders          $  3,226,784    (3,986,564) $(2,706,984) $(7,438,492)
                       ============  ============  ===========  =========== 
                                                                            
Net income (loss) per                                                       
 share attributable to                                                      
 common stockholders -                                                      
 basic                 $       0.10  $      (0.19) $     (0.10) $     (0.36)
                                                                            
Net income (loss) per                                                       
 share attributable to                                                      
 common stockholders -                                                      
 diluted               $       0.03  $      (0.19) $     (0.10) $     (0.36)
                                                                            
Weighted average                                                            
 common stock shares                                                        
 outstanding used in                                                        
 the basic net income                                                       
 (loss) per share                                                           
 calculation             30,915,938    21,511,904   27,339,362   20,726,205 
                                                                            
Weighted average                                                            
 common stock shares                                                        
 outstanding used in                                                        
 the diluted net                                                            
 income (loss) per                                                          
 share calculation      104,431,537    21,511,904   27,339,362   20,726,205 
                                                                            
                                                                            
                  PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY                 
                         CONSOLIDATED BALANCE SHEETS                        
                                                                            
                                                December 31,   December 31, 
                                                    2016           2015     
                                               -------------  ------------- 
                    ASSETS                                                  
CURRENT ASSETS                                                              
Cash and cash equivalents                      $     138,363  $     116,783 
Accounts receivable, net of $28,169 reserve at                              
 December 31, 2016 and $0 at December 31, 2015       281,320        113,256 
Inventories, net of $20,000 reserve at                                      
 December 31, 2016 and $50,000 at December 31,                              
 2015                                                905,284      1,038,371 
Prepaid income taxes                                   7,405          7,381 
Prepaid expenses and other current assets            258,103        213,926 
                                               -------------  ------------- 
  Total current assets                             1,590,475      1,489,717 
Investment in available-for-sale equity                                     
 securities                                           25,865        294,522 
Property and equipment, net                            9,413         20,149 
                                               -------------  ------------- 
TOTAL ASSETS                                   $   1,625,753  $   1,804,388 
                                               =============  ============= 
                                                                            
     LIABILITIES AND STOCKHOLDERS' DEFICIT                                  
CURRENT LIABILITIES                                                         
Accounts payable                               $     407,249  $     941,389 
Accrued employee compensation                        249,596        176,009 
Accrued professional fees and other                  956,884        821,088 
Deferred revenue                                     159,654        140,878 
Revolving note payable, net of unamortized                                  
 debt discounts of $637,030 and $0,                                         
 respectively                                        612,970              - 
Convertible debt, net of unamortized discounts                              
 of $2,235,839 and $0, respectively                4,005,702        100,000 
Other debt, net of unamortized discounts of                                 
 $380 and $3,041, respectively                       238,157        151,628 
Warrant derivative liabilities                     1,685,108      3,295,976 
Conversion option derivative liabilities             951,059      3,940,791 
                                               -------------  ------------- 
  Total current liabilities                        9,266,379      9,567,759 
                                               -------------  ------------- 
LONG TERM LIABILITIES                                                       
Related party convertible debt, net of                                      
 unamortized debt discounts of $165,611 and                                 
 $0, respectively                                    125,523              - 
Convertible debt, net of unamortized discounts                              
 of $740,628 and $5,223,658, respectively            529,742        177,342 
Deferred revenue                                      87,527         36,935 
                                               -------------  ------------- 
TOTAL LIABILITIES                                 10,009,171      9,782,036 
                                               -------------  ------------- 
COMMITMENTS AND CONTINGENCIES                                               
STOCKHOLDERS' DEFICIT                                                       
Series D Convertible Preferred Stock, $.01 par                              
 value; 850 shares authorized; 300 shares                                   
 issued and outstanding on December 31, 2016                                
 and 2015, respectively (Liquidation value of                               
 $300,000)                                                 3              3 
Series G Convertible Preferred Stock, $.01 par                              
 value; 240,000 shares authorized; 86,570                                   
 shares issued and outstanding on December 31,                              
 2016 and 2015, respectively                             866            866 
Series H Convertible Preferred Stock, $.01 par                              
 value; 10,000 shares authorized; 10,000                                    
 shares issued and outstanding on December 31,                              
 2016 and 2015, respectively                             100            100 
Series H2 Convertible Preferred Stock, $.01                                 
 par value; 21 shares authorized; 21 shares                                 
 issued and outstanding on December 31, 2016                                
 and 2015, respectively                                    -              - 
Series J Convertible Preferred Stock, $.01 par                              
 value; 6,250 shares authorized; 3,521 and                                  
 3,546 shares issued and outstanding on                                     
 December 31, 2016 and 2015, respectively                 35             36 
Series K Convertible Preferred Stock, $.01 par                              
 value; 15,000 shares authorized; 6,816 and                                 
 11,416 shares issued and outstanding on                                    
 December 31, 2016 and 2015, respectively                 68            114 
Common stock, $.01 par value; 100,000,000                                   
 shares authorized; 30,999,839 and 23,004,898                               
 shares issued and outstanding on December 31,                              
 2016 and 2015, respectively                         309,998        230,050 
Warrants to acquire common stock                   6,325,102      5,416,681 
Additional paid-in capital                        27,244,600     26,036,733 
Accumulated other comprehensive loss                       -       (105,025)
Accumulated deficit                              (42,264,190)   (39,557,206)
                                               -------------  ------------- 
  Total stockholders' deficit                     (8,383,418)    (7,977,648)
                                               -------------  ------------- 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT    $   1,625,753  $   1,804,388 
                                               =============  ============= 

Investor Contacts:
Richard T. Schumacher
President & CEO
(508) 230-1828 (T)

Jeffrey N. Peterson
Chairman of the Board
(650) 812-8121 (T)

Back to news